COMPANY PROFILE

Mustbio

Explore full profile

Mustbio is based on multiple specific antibodies platform technology

Seoul, South KoreaFounded 2021Biotech & Life Sciences

Valuation $50–100M Last recorded · 2026

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Mustbio

Mustbio is a biotechnology company specializing in the development of anti-arterial drugs using advanced multiple antibodies platform technologies. The company focuses on creating innovative treatments for immunological cancer, leveraging its proprietary PILElNE technology. Mustbio operates in the pharmaceutical and biotechnology market, serving clients in the healthcare and medical research sectors. The business model revolves around research and development (R&D) partnerships, which are crucial for the successful creation of new drugs. Revenue is generated through collaborations, licensing agreements, and potential future sales of developed drugs. Mustbio's commitment to R&D and strategic partnerships positions it as a key player in the biotech industry.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2021
Headquarters: Seoul, South Korea
Employees: 5
Open positions: None listed
Dealroom signal: 47.2/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES C✓Equity / VC	Mar 2026	$29M	$79M	Korea Investment Partners · Partners Investment · Atinum Investment · WONIK Investment Partners	↗
SERIES B✓Equity / VC	Dec 2022	$13M	$50M	Partners Investment	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Mustbio website traffic

Latest recorded traffic for Mustbio is 1.8K monthly website visits, down 71% over the last three months. Mustbio's team grew 0% over the past year.

Latest monthly visits1.8K 3-month web change-71% 1-year team growth0%

Monthly website visitsAug 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
JLJunhe LeagueRecombinant protein drug developer	Hangzhou, China	Operational	—	$55M	$110M
RPRectify PharmaceuticalsBreakthrough ABC transporter platform enabling rapid discovery of small molecule therapies for liver, biliary, eye, CNS, and cardiometabolic diseases	Cambridge, United States	Operational
SPStargazer PharmaceuticalsAn ophthalmic biotech company focused on the development of a novel treatment option for a genetic orphan retinal disease with significant unmet medical needs	Boston, United States	Operational
RPRegenacy PharmaceuticalsDeveloping ricolinostat to treat diabetic, chemotherapy-induced and inherited peripheral neuropathies	Waltham, United States	Operational
YBYaohai BioA genetic engineering protein drug developer	China	Operational
MBMereo BiopharmaAcquiring and developing therapeutics for rare diseases and oncology	London, United Kingdom	Operational
ABAzurRx BioPharmaAzurRx BioPharma aims to become a leader in developing non-systemic, recombinant protein therapies	Boca Raton, United States	Operational
GLGlycomineDeveloping orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist	San Carlos, United States	Operational